{"contentid": 488272, "importid": NaN, "name": "John Robinson jumps from Pfizer to become Cogent CSO", "introduction": "US biotech Cogent Biosciences has named John Robinson the company\u00e2\u0080\u0099s chief scientific officer (CSO).", "content": "<p>US biotech Cogent Biosciences (Nasdaq: COGT) has named John Robinson as the company&rsquo;s chief scientific officer (CSO).</p>\n<p>Dr Robinson will lead the newly-created Cogent Research Team, with a focus on discovering and developing new small molecule therapies for patients fighting rare, genetically-driven diseases.</p>\n<p>Andrew Robbins, president and chief executive of Cogent, said: &ldquo;John&rsquo;s expertise and seasoned leadership make him ideally suited to lead this new team of world class scientists. Given the team&rsquo;s impressive experience and accomplishments, we are excited for Cogent Biosciences&rsquo; future and the opportunity to expand our pipeline and deliver novel precision therapies for patients.&rdquo;</p>\n<p>The Cogent Research Team, based in Boulder, Colorado, will focus on pioneering best-in-class, small molecule therapeutics to both improve upon existing drugs with clear limitations, as well as create new breakthroughs for diseases where others have been unable to find solutions.</p>\n<p>Dr Robinson joins from US pharma giant Pfizer (NYSE: PFE), where he most recently served as vice president, medicinal chemistry.</p>\n<p>For more than 15 years prior to this, he was a senior member of the Array BioPharma scientific leadership team, a group responsible for developing more than 25 Investigational New Drug applications including five that won US approval. Array was acquired by Pfizer in 2019.</p>\n<p>Cogent&rsquo;s most advanced clinical program, CGT9486, is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. It is due to enter three late-stage clinical trials starting this year, beginning with advanced systemic mastocytosis.</p>", "date": "2021-04-07 12:40:00", "meta_title": NaN, "meta_keywords": NaN, "meta_description": NaN, "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-04-07 12:32:09", "updated": "2021-04-07 13:37:18", "access": NaN, "url": "https://www.thepharmaletter.com/article/john-robinson-jumps-from-pfizer-to-become-cogent-cso", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "john_robinson_cogent_large.jpg", "image2id": "john_robinson_cogent_small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Pharmaceutical", "therapy area_tag": "Genetics, Hematology, Rare diseases", "topic_tag": "Boardroom, Management", "geography_tag": "USA", "company_tag": "Cogent Biosciences, Pfizer", "drug_tag": NaN, "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": "John Robinson", "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-04-07 12:40:00"}